ReNeuron Group (RENE); revenue at £6,030,000

Published on 06-12-2019 09:42:37
Author Sparks Team

ReNeuron Group announced its interim results for the six months ending 30 September 2019. The company reduced its loss and cash consumed by operations for the period to £3.90m and £5.15m, respectively. An upfront payment of £5.40m, net of withholding tax, was received pertaining to licence agreement with Fosun Pharma. Cash, cash equivalents and bank deposits stood at £21.27m as of 30 September 2019.

ReNeuron Group announced its interim results for the six months ending 30 September 2019. The company reduced its loss and cash consumed by operations for the period to £3.90m and £5.15m, respectively. An upfront payment of £5.40m, net of withholding tax, was received pertaining to licence agreement with Fosun Pharma. Cash, cash equivalents and bank deposits stood at £21.27m as of 30 September 2019.

In the CTX stem cell therapy candidate for stroke disability, clinical trial protocol amendments and other initiatives are in place to accelerate patient recruitment in ongoing US Phase 2b clinical trial. The overall size of the Phase 2b study increased to 130 patients, with top-line data expected in mid-2021.

In the CTX stem cell therapy candidate for stroke disability, clinical trial protocol amendments and other initiatives are in place to accelerate patient recruitment in ongoing US Phase 2b clinical trial. The overall size of the Phase 2b study increased to 130 patients, with top-line data expected in mid-2021.

Share this with friends and colleagues